Advanced Solid TumorPhase 1/2NCT07508761
IPG7236 Combined With Toripalimab in Participants With Advanced Solid Tumors
A Phase 1/2 study testing IPG7236 and Toripalimab Injection in people with Advanced Solid Tumor, run by Nanjing Immunophage Biotech Co., Ltd at 1 site in China.
Trial summary
Phase 1/2 Study for IPG7236 Combined With Toripalimab in Participants With Advanced Solid Tumors Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Advanced Solid Tumor
- What is being tested?
- IPG7236 and Toripalimab Injection
- Type of treatment
- Pill or oral medicine, Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 52 participants
- Where
- 1 siteChina
- Study dates
- 16 Jun 2026to 30 Jul 2029
- Phase
- Phase 1/2
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Written informed consent must be obtained before any study procedure is performed.
- Men or women 18 years of age or older.
- Histologically or cytologically confirmed advanced or recurrent malignant solid tumors that are metastatic or unresectable. (Subjects must submit tumor tissue sections from within the past 5 years for CCR8 expression testing. For subjects without paraffin-embedded tissues, a fine-needle aspiration biopsy may be performed. Subjects who cannot provide tumor tissue sections or undergo biopsy are only eligible for inclusion during the dose escalation phase. During the dose expansion phase, CCR8 positivity must be known or tumor tissue sections must be provided with confirmed CCR8 expression.)
- Subjects must have failed or been intolerant to standard antitumor therapy, or lack a standard treatment regimen, or be deemed by the investigator as currently unsuitable for standard therapy.
- According to the RECIST 1.1 criteria, there is at least one measurable lesion.
- Life expectancy ≥ 3 months.
Show all 15Show fewer
- Subjects must be able to swallow the oral investigational drug.
- The ECOG performance status score is 0 or 1.
- Sufficient hematologic and organ function, with the following laboratory test values:
- Hematology: Absolute Neutrophil Count (ANC) ≥ 1.5×10⁹/L; platelet count ≥ 75×10⁹/L; Hemoglobin ≥ 9 g/dL; lymphocytes ≥ 0.8×10⁹/L;
- Renal: Creatinine clearance calculated by the Cockcroft-Gault method ≥ 50 mL/min or serum creatinine ≤ 1.5× upper limit of normal (ULN);
- Hepatic: Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) ≤ 3×ULN, or ≤ 5×ULN for subjects with liver metastases; total bilirubin ≤ 1.5×ULN, or ≤ 3×ULN for subjects with Gilbert syndrome or genetically equivalent conditions;
- Coagulation: Prothrombin time (PT) and activated partial thromboplastin time (aPTT) ≤ 1.5× upper limit of normal (ULN).
- Patients must be willing and able to comply with all scheduled visits, treatments, laboratory tests, and other study requirements.
- Male and female participants of reproductive potential who engage in heterosexual sexual behavior must agree to use reliable contraceptive methods (hormonal, barrier, or abstinence,etc.) for at least 4 months during the trial period and after the last study drug administration (refer to Appendix 13.1 of the protocol)
Who cannot join
- Primary malignant tumors of the central nervous system or malignant tumors associated with human immunodeficiency virus (HIV) .
- Previous use of CCR8-targeted therapy.
- Received the following treatment within the specified time frame:
- Planned major surgery within 4 weeks prior to the first dose administration (excluding minor procedures such as vascular access placement, gastrointestinal/biliary stent placement, or biopsy);
- Immunotherapy or biological therapy administered within 28 days prior to the initial administration;
- Chemotherapy <21 days prior to the first dose, or mitomycin or nitrosoureas < 42 days prior, or oral fluoropyrimidines < 14 days prior;
Show all 30Show fewer
- Targeted small-molecule therapy or traditional Chinese medicine with antitumor indications administered within 14 days prior to the initial dose;
- Hormone therapy or other adjuvant therapies are not permitted if initiated within 14 days prior to the first dose. Exceptions: anti-estrogen therapy, bisphosphonates, RANKL monoclonal antibodies, somatostatin analogs, and leuprorelin are permitted if initiated ≥ 14 days prior to the first dose.
- Radiotherapy administered within 28 days prior to the first dose, or palliative radiotherapy within 14 days prior. Exception: Palliative radiotherapy (e.g., for analgesia) may be performed during the study drug administration period, provided that it is not permitted during the DLT observation period, any previously induced adverse events from radiotherapy have been resolved to grade <2, and the radiotherapy was not directed at the target lesion.
- Other investigational or treatments administered within 28 days prior to the first dose;
- Any previous allogeneic tissue/solid organ transplantation, including allogeneic stem cell transplantation;
- Previous treatment-related toxicity has not yet resolved to a level of ≤ 1 per National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v6.0 or to the specified levels in the inclusion/exclusion criteria (except for safety risks deemed by the investigator as not significant, such as alopecia, grade 2 peripheral neuropathy, hypothyroidism or hyperthyroidism, or other endocrine disorders well-controlled by hormone replacement therapy).
- In combination with other active malignancies (excluding basal cell carcinoma of the skin, cervical carcinoma in situ, or superficial bladder cancer with no evidence of disease after potentially curative treatment; For other patients with previous malignant tumors who have survived without disease for more than 3 years, they are also (acceptable).
- Immune-related adverse events (irAEs) of grade ≥ 3 or those leading to treatment discontinuation during prior immunotherapy, or grade ≥ 2 immune-mediated myocarditis, or treatment discontinuation due to allergic or infusion-related reactions.
- Diagnosis of primary or acquired immunodeficiency, or receipt of systemic glucocorticoids or any other form of immunosuppressive therapy within 7 days prior to the first dose. Exceptions: intraocular, intranasal, intra-articular, inhaled, or systemic glucocorticoids (prednisone dose ≤ 10 mg/day or equivalent, or doses used for adrenal replacement therapy), as well as a single dose of immunosuppressive medication for contrast agent allergy prophylaxis (if no active autoimmune disease is present).
- History of autoimmune disease requiring systemic therapy or active autoimmune diseases (i.e., requiring glucocorticoids or immunosuppressive agents for disease control) within 2 years prior to study initiation are eligible, provided they do not require immunosuppressive therapy for conditions such as type 1 diabetes mellitus, vitiligo, psoriasis,hypothyroidism, or hyperthyroidism.
- Known severe or life-threatening allergic reactions to humanized monoclonal antibodies (mAbs) or intravenous immunoglobulin (Ig) preparations; known hypersensitivity to any investigational drug, its analogues, or excipients.
- Untreated brain metastases, meningeal metastases, or spinal cord compression not definitively treated with surgery or radiotherapy. (Patients with brain metastases who have stabilized without symptoms after prior treatment and have not received high-dose steroid therapy are eligible for enrollment.)
- Uncontrolled or requiring intravenous anti-infective therapy for active bacterial, fungal, or viral infections.
- Active hepatitis B virus (HBV) and/or hepatitis C virus (HCV) and/or HIV:
- Participants must be negative for hepatitis B surface antigen (HBsAg).
- For HCV antibody-positive subjects, the HCV RNA quantification must be below the research center's detection limit.
- HIV test must be negative at screening;
- Administration of live or live-attenuated vaccines within 4 weeks prior to the first dose (inactivated vaccines, viral vector vaccines, and mRNA vaccines are permitted; seasonal vaccines should be completed prior to the first dose).
- The serum pregnancy test is positive within 3 days before the first dose.
- Lactating female subjects.
- Pneumonitis, interstitial lung disease, or severe radiation pneumonitis (excluding localized radiation pneumonitis) requiring glucocorticoid therapy.
- Patients with clinically uncontrollable ascites or pleural effusion are deemed unsuitable for enrollment by the investigator.
- Symptomatic cardiovascular or cerebrovascular disease; accident/stroke or myocardial infarction (MI), unstable angina, congestive heart failure (NYHA class III or higher), or severe arrhythmias uncontrolled by pharmacotherapy within 6 months prior to enrollment; mean QT interval corrected for heart rate using the Fridericia formula (QTcF) ≥ 470 ms.
- Any medical or social condition that may expose subjects to higher risks, affect compliance, or obscure the interpretation of safety or other clinical study data
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site, 1 recruiting
- Recruiting
Shanghai Gaobo Tumor Hospital
Shanghai, PuDongXinQu, 200120
Jin Li, +86-021-60571204, lijin@csco.org.cn
About this study
Official title: A Phase I/II Multicenter, Non-randomized, Open-label, Dose Escalation and Expansion Study of IPG7236 Combined With Toripalimab Treatment of Advanced Solid Tumors in Adult Patients to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity
Phase 1/2 Study for IPG7236 Combined With Toripalimab in Participants With Advanced Solid Tumors
Read the detailed description
This is a phase 1/2, multicenter, non-randomized, open-label, dose-escalation and dose-expansion study. Part A (dose escalation) will adopt a standard "3+3" design with two cohorts (IPG7236 500 mg BID + Toripalimab 240 mg Q3W; IPG7236 800 mg BID + Toripalimab 240 mg Q3W) to determine the MTD and/or RP2D. Part B (dose expansion) will enroll approximately 40 CCR8-positive advanced solid tumor patients to further evaluate safety,tolerability and preliminary antitumor activity. The transition from Part A to Part B will be triggered after confirmation of RP2D based on safety, tolerability, PK and preliminary efficacy data.
- Conditions
- Advanced Solid Tumor
- Being tested
- IPG7236, Toripalimab Injection
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
IPG7236Drug
IPG7236: Part A: 500 mg BID or 800 mg BID, the dose in Part B is the RP2D confirmed in Part A, Oral (fasting: 1 hour before meal or 2 hours after meal, every 12±2 hours), Continuous daily administration, 21-day treatment cycle,Until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons for withdrawal
Toripalimab InjectionDrug
Toripalimab Injection: 240 mg , Q3W, 21-day treatment cycle, the first infusion lasts at least 60 minutes; if well tolerated, subsequent infusions can be shortened to 30 minutes.
| Study group | Role | What they receive |
|---|---|---|
| Part A（Cohort 1） ：IPG7236 500mg & Toripalimab | Experimental | 3-6 subjects in this cohort will receive IPG7236 500 mg BID and Toripalimab Injection 240 mg， Dose-escalation cohort with 3+3 design; DLT assessment period is 21 days. Receives: Drug: IPG7236; Drug: Toripalimab Injection |
| Part A（Cohort 2）：IPG7236 800mg& Toripalimab | Experimental | 3-6 subjects in this cohort will receive IPG7236 800 mg BID and Toripalimab Injection 240 mg，Dose-escalation cohort with 3+3 design; enrolled sequentially after Cohort 1; DLT assessment period is 21 days. Receives: Drug: IPG7236; Drug: Toripalimab Injection |
| Part B：IPG7236 RP2D & Toripalimab | Experimental | 40 subjects in this cohort will receive IPG7236 at the RP2D BID and Toripalimab Injection 240 mg Receives: Drug: IPG7236; Drug: Toripalimab Injection |
What is being measured
The primary outcome is the main question the study is designed to answer.
Incidence of Dose-Limiting Toxicity (DLT)
Dose-Limiting Toxicity (DLT) is treatment-related adverse events (excluding disease progression/external causes) per NCI CTCAE v6.0, occurring within Cycle 1 Day 1-21,1) Unexplained death; 2) Hematological: Grade 4 neutropenia >7d; Grade ≥3 febrile neutropenia; Grade 4 thrombocytopenia or Grade 3 with clinical bleeding; Grade 4 anemia; 3) Non-hematological: Grade ≥3 (exceptions: Grade 3 nausea/vomiting/diarrhea <3d with antiemetics; Grade 3 fatigue <1w; pancreatitis-unrelated Grade ≥3 amylase/lipase; Grade ≥3 electrolyte disturbance resolving within 72h without complications; asymptomatic isolated lab abnormalities); Hepatotoxicity: Hy's Law (ALT/AST >3×ULN + total bilirubin >2×ULN + ALP <2×ULN); AST/ALT >8×ULN (or >8×baseline for liver metastasis); AST/ALT >5×ULN (or >5×baseline for liver metastasis) ≥14d; Other Grade 4 non-hematological toxicity; 4) Toxicity requiring permanent study drug discontinuation or <75% planned administration. Infusion-related reactions are not DLT;
Measured: Up to 21 days after first dose (Cycle 1): To determine the DLT according to NCI CTCAE v6.0, and define the Maximum Tolerated Dose (MTD) and RP2D of IPG7236 in combination with toripalimab
Percentage of patients with adverse events
Measured: From first dose to 90 days after last dose or initiation of new anti-cancer therapy, whichever comes first
Secondary outcomes (10)
Objective Response Rate (ORR) per iRECIST v1.1
Objective Response Rate (ORR) is defined as the percentage of participants with a best overall response of complete response (CR) or partial response (PR) per iRECIST v1.1 criteria.
Measured: From first dose to disease progression or death (up to 24 months)
Disease Control Rate (DCR) per iRECIST v1.1
Disease Control Rate (DCR) is defined as the percentage of participants with a best overall response of complete response (CR), partial response (PR), or stable disease (SD) per iRECIST v1.1 criteria.
Measured: From first dose to disease progression or death (up to 24 months)
Duration of Response (DoR) per iRECIST v1.1
Duration of Response (DoR) is defined as the time from first documentation of objective response (CR or PR) to first documentation of progressive disease (PD) or death due to any cause, per iRECIST v1.1 criteria.
Measured: From first documentation of objective response (CR or PR) to first documentation of progressive disease (PD) or death (up to 24 months)
Progression-Free Survival (PFS) per iRECIST v1.1
Progression-Free Survival (PFS) is defined as the time from first dose to first documentation of progressive disease (PD) per iRECIST v1.1 criteria or death due to any cause, whichever occurs first.
Measured: From first dose to disease progression or death (up to 24 months)
Overall Survival (OS) per iRECIST v1.1
Overall Survival (OS) is defined as the time from first dose to death due to any cause.
Measured: From first dose to death due to any cause (up to 24 months)
Peak Plasma Concentration (Cmax) of IPG7236
Peak plasma concentration of IPG7236, determined from plasma concentration-time profiles obtained at preset time points.
Measured: From first dose to end of treatment, assessed up to 24 months
Trough Plasma Concentration (Cmin) of IPG7236
Trough plasma concentration of IPG7236, determined from plasma concentration-time profiles obtained at preset time points.
Measured: From first dose to end of treatment, assessed up to 24 months
Area Under the Plasma Concentration-Time Curve (AUC) of IPG7236
Area under the plasma concentration-time curve of IPG7236, calculated using non-compartmental analysis from plasma samples collected at preset time points.
Measured: From first dose to end of treatment, assessed up to 24 months
Time to Peak Plasma Concentration (Tmax) of IPG7236
Time to reach peak plasma concentration of IPG7236, determined from plasma concentration-time profiles obtained at preset time points.
Measured: From first dose to end of treatment, assessed up to 24 months
Elimination Half-Life (T1/2) of IPG7236
Elimination half-life of IPG7236, calculated from the terminal phase of the plasma concentration-time curve obtained at preset time points.
Measured: From first dose to end of treatment, assessed up to 24 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Apr 2026
- Study start16 Jun 2026
- Primary completion30 Dec 2028 (estimated)
- Study completion30 Jul 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Advanced Solid TumorStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1/2
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 52 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Nanjing Immunophage Biotech Co., Ltd
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07508761
- Sponsor's protocol ID
- IPG7236-C003
- Status last verified
- Mar 2026
- First submitted
- 23 Mar 2026
- Last updated
- 29 Jun 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 29 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase I/II Multicenter, Non-randomized, Open-label, Dose Escalation and Expansion Study of IPG7236 Combined With Toripalimab Treatment of Advanced Solid Tumors in Adult Patients to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity
- ClinicalTrials.gov ID
- NCT07508761
- Acronym / sponsor ID
- IPG7236-C003
- Conditions
- Advanced Solid Tumor
- Phase
- Phase 1/2
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 52 participants (estimated)
- Lead sponsor
- Nanjing Immunophage Biotech Co., LtdIndustry (pharma, biotech, devices)
- Study start
- 16 Jun 2026 (actual)
- Primary completion
- 30 Dec 2028 (estimated)
- Study completion
- 30 Jul 2029 (estimated)
- First posted
- 2 Apr 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Phase 1/2 Study for IPG7236 Combined With Toripalimab in Participants With Advanced Solid Tumors
Detailed description
This is a phase 1/2, multicenter, non-randomized, open-label, dose-escalation and dose-expansion study. Part A (dose escalation) will adopt a standard "3+3" design with two cohorts (IPG7236 500 mg BID + Toripalimab 240 mg Q3W; IPG7236 800 mg BID + Toripalimab 240 mg Q3W) to determine the MTD and/or RP2D. Part B (dose expansion) will enroll approximately 40 CCR8-positive advanced solid tumor patients to further evaluate safety,tolerability and preliminary antitumor activity. The transition from Part A to Part B will be triggered after confirmation of RP2D based on safety, tolerability, PK and preliminary efficacy data.
Study design
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Part A（Cohort 1） ：IPG7236 500mg & Toripalimab | Experimental | Drug: IPG7236, Drug: Toripalimab Injection3-6 subjects in this cohort will receive IPG7236 500 mg BID and Toripalimab Injection 240 mg， Dose-escalation cohort with 3+3 design; DLT assessment period is 21 days. |
| Part A（Cohort 2）：IPG7236 800mg& Toripalimab | Experimental | Drug: IPG7236, Drug: Toripalimab Injection3-6 subjects in this cohort will receive IPG7236 800 mg BID and Toripalimab Injection 240 mg，Dose-escalation cohort with 3+3 design; enrolled sequentially after Cohort 1; DLT assessment period is 21 days. |
| Part B：IPG7236 RP2D & Toripalimab | Experimental | Drug: IPG7236, Drug: Toripalimab Injection40 subjects in this cohort will receive IPG7236 at the RP2D BID and Toripalimab Injection 240 mg |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (15 listed)
- Written informed consent must be obtained before any study procedure is performed.
- Men or women 18 years of age or older.
- Histologically or cytologically confirmed advanced or recurrent malignant solid tumors that are metastatic or unresectable. (Subjects must submit tumor tissue sections from within the past 5 years for CCR8 expression testing. For subjects without paraffin-embedded tissues, a fine-needle aspiration biopsy may be performed. Subjects who cannot provide tumor tissue sections or undergo biopsy are only eligible for inclusion during the dose escalation phase. During the dose expansion phase, CCR8 positivity must be known or tumor tissue sections must be provided with confirmed CCR8 expression.)
- Subjects must have failed or been intolerant to standard antitumor therapy, or lack a standard treatment regimen, or be deemed by the investigator as currently unsuitable for standard therapy.
- According to the RECIST 1.1 criteria, there is at least one measurable lesion.
Key exclusion criteria (30 listed)
- Primary malignant tumors of the central nervous system or malignant tumors associated with human immunodeficiency virus (HIV) .
- Previous use of CCR8-targeted therapy.
- Received the following treatment within the specified time frame:
- Previous treatment-related toxicity has not yet resolved to a level of ≤ 1 per National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v6.0 or to the specified levels in the inclusion/exclusion criteria (except for safety risks deemed by the investigator as not significant, such as alopecia, grade 2 peripheral neuropathy, hypothyroidism or hyperthyroidism, or other endocrine disorders well-controlled by hormone replacement therapy).
- In combination with other active malignancies (excluding basal cell carcinoma of the skin, cervical carcinoma in situ, or superficial bladder cancer with no evidence of disease after potentially curative treatment; For other patients with previous malignant tumors who have survived without disease for more than 3 years, they are also (acceptable).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| IPG7236IPG7236: Part A: 500 mg BID or 800 mg BID, the dose in Part B is the RP2D confirmed in Part A, Oral (fasting: 1 hour before meal or 2 hours after meal, every 12±2 hours), Continuous daily administration, 21-day treatment cycle,Until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons for withdrawal | Drug | Part A（Cohort 1） ：IPG7236 500mg & Toripalimab, Part A（Cohort 2）：IPG7236 800mg& Toripalimab, Part B：IPG7236 RP2D & Toripalimab |
| Toripalimab InjectionToripalimab Injection: 240 mg , Q3W, 21-day treatment cycle, the first infusion lasts at least 60 minutes; if well tolerated, subsequent infusions can be shortened to 30 minutes. | Drug | Part A（Cohort 1） ：IPG7236 500mg & Toripalimab, Part A（Cohort 2）：IPG7236 800mg& Toripalimab, Part B：IPG7236 RP2D & Toripalimab |
Primary outcome
Incidence of Dose-Limiting Toxicity (DLT)
Time frame: Up to 21 days after first dose (Cycle 1): To determine the DLT according to NCI CTCAE v6.0, and define the Maximum Tolerated Dose (MTD) and RP2D of IPG7236 in combination with toripalimab
Dose-Limiting Toxicity (DLT) is treatment-related adverse events (excluding disease progression/external causes) per NCI CTCAE v6.0, occurring within Cycle 1 Day 1-21,1) Unexplained death; 2) Hematological: Grade 4 neutropenia >7d; Grade ≥3 febrile neutropenia; Grade 4 thrombocytopenia or Grade 3 with clinical bleeding; Grade 4 anemia; 3) Non-hematological: Grade ≥3 (exceptions: Grade 3 nausea/vomiting/diarrhea <3d with antiemetics; Grade 3 fatigue <1w; pancreatitis-unrelated Grade ≥3 amylase/lipase; Grade ≥3 electrolyte disturbance resolving within 72h without complications; asymptomatic isolated lab abnormalities); Hepatotoxicity: Hy's Law (ALT/AST >3×ULN + total bilirubin >2×ULN + ALP <2×ULN); AST/ALT >8×ULN (or >8×baseline for liver metastasis); AST/ALT >5×ULN (or >5×baseline for liver metastasis) ≥14d; Other Grade 4 non-hematological toxicity; 4) Toxicity requiring permanent study drug discontinuation or <75% planned administration. Infusion-related reactions are not DLT;
Percentage of patients with adverse events
Time frame: From first dose to 90 days after last dose or initiation of new anti-cancer therapy, whichever comes first
10 secondary outcomes
Objective Response Rate (ORR) per iRECIST v1.1
Time frame: From first dose to disease progression or death (up to 24 months)
Disease Control Rate (DCR) per iRECIST v1.1
Time frame: From first dose to disease progression or death (up to 24 months)
Duration of Response (DoR) per iRECIST v1.1
Time frame: From first documentation of objective response (CR or PR) to first documentation of progressive disease (PD) or death (up to 24 months)
Progression-Free Survival (PFS) per iRECIST v1.1
Time frame: From first dose to disease progression or death (up to 24 months)
Overall Survival (OS) per iRECIST v1.1
Time frame: From first dose to death due to any cause (up to 24 months)
Peak Plasma Concentration (Cmax) of IPG7236
Time frame: From first dose to end of treatment, assessed up to 24 months
Trough Plasma Concentration (Cmin) of IPG7236
Time frame: From first dose to end of treatment, assessed up to 24 months
Area Under the Plasma Concentration-Time Curve (AUC) of IPG7236
Time frame: From first dose to end of treatment, assessed up to 24 months
Time to Peak Plasma Concentration (Tmax) of IPG7236
Time frame: From first dose to end of treatment, assessed up to 24 months
Elimination Half-Life (T1/2) of IPG7236
Time frame: From first dose to end of treatment, assessed up to 24 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 Jun 2026.
- Individual participant dataSharing planned: No
Related trials for Advanced Solid Tumor
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
Active, not recruitingPhase 1
A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK043 in Patients With Advanced Solid Tumor
Neoplasms
RecruitingPhase 1/2
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Locally Advanced Solid Tumor, Metastatic Solid Tumor
Active, not recruitingPhase 2
Testing AZD5363 as a Potential Targeted Treatment in Cancers With AKT Genetic Changes (MATCH-Subprotocol Y)
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
RecruitingPhase 1/2
Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1/2 study testing IPG7236 and Toripalimab Injection in people with Advanced Solid Tumor, run by Nanjing Immunophage Biotech Co., Ltd at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 15 inclusion and 30 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 29 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this combined phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact jian fei wang, CSO (+86-21-34782827, jfwang@immunophage.com.cn), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Incidence of Dose-Limiting Toxicity (DLT) (time frame: Up to 21 days after first dose (Cycle 1): To determine the DLT according to NCI CTCAE v6.0, and define the Maximum Tolerated Dose (MTD) and RP2D of IPG7236 in combination with toripalimab). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Jun 2026.